The Washington manual hematology and oncology subspecialty consult
著者
書誌事項
The Washington manual hematology and oncology subspecialty consult
（Washington manual subspecialty consult series）
Wolters Kluwer Health/Lippincott Williams & Wilkins, c2012
3rd ed.
- タイトル別名
-
Hematology and oncology subspecialty consult
大学図書館所蔵 件 / 全4件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
内容説明・目次
内容説明
"The Washington Manual Subspecialty Consult Series" is designed to provide quick access to the essential information needed to evaluate a patient on a subspecialty consult service. "The Washington Manual of Hematology and Oncology Subspecialty Consult" has been completely reviewed, revised, and follows the bulleted format and template of "The Washington Manual of Medical Therapeutics, 33/e" to allow for quick, readily accessible information. This edition has been updated to include new standards in the treatment of malignancies and hematologic disorders, mechanisms of action of new therapeutic agents, and the current use of molecular prognostic factors. The information in each chapter is now presented in a consistent format, with important references cited. The Manual is a practical reference for fellows, residents, and medical students rotating on hematology and oncology subspecialty services. Most of the authors are hematology-oncology fellows or internal medicine residents, the physicians who have recent experience with the issues and questions that arise in the course of training in these subspecialties.
Primary care practitioners and other health care professionals also will find this manual useful as a quick reference source in hematology and oncology. This title: includes new, templated format same as "The Washington University Medical Therapeutics, 33/e"; contains synopsis of symptoms, signs, and problems encountered in their daily workflow in a bulleted format for quick salient points; and, includes new standards in the treatment of malignancies and hematologic disorders, mechanisms of action of new therapeutic agents, and the current use of molecular prognostic factors.
「Nielsen BookData」 より